Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Function of hepatocyte growth factor in gastric cancer proliferation and invasion

  • Koh, Sung Ae (Department of Hematology-Oncology, Yeungnam University College of Medicine) ;
  • Lee, Kyung Hee (Department of Hematology-Oncology, Yeungnam University College of Medicine)
  • Received : 2019.01.21
  • Accepted : 2020.01.28
  • Published : 2020.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Cancer incidence has been increasing steadily and is the leading cause of mortality worldwide. Gastric cancer is still most common malignancy in Korea. Cancer initiation and progression are multistep processes involving various growth factors and their ligands. Among these growth factors, we have studied hepatocyte growth factor (HGF), which is associated with cell proliferation and invasion, leading to cancer and metastasis, especially in gastric cancer. We explored the intercellular communication between HGF and other surface membrane receptors in gastric cancer cell lines. Using complimentary deoxyribonucleic acid microarray technology, we found new genes associated with HGF in the stomach cancer cell lines, NUGC-3 and MKN-28, and identified their function within the HGF pathway. The HGF/N-methyl-N'-nitroso-guanidine human osteosarcoma transforming gene (c-MET) axis interacts with several molecules including E-cadherin, urokinase plasminogen activator, KiSS-1, Jun B, and lipocalin-2. This pathway may affect cell invasion and metastasis or cell apoptosis and is therefore associated with tumorigenesis and metastasis in gastric cancer.

Keywords

References

  1. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999;9:211-20. https://doi.org/10.1006/scbi.1998.0091
  2. Schmitt FC, Soares R. TGF-alpha and angiogenesis. Am J Surg Pathol 1999;23:358-9. https://doi.org/10.1097/00000478-199903000-00023
  3. Botta M, Manetti F, Corelli F. Fibroblast growth factors and their inhibitors. Curr Pharm Des 2000;6:1897-924. https://doi.org/10.2174/1381612003398528
  4. Mooradian DL, Diglio CA. Production of a transforming growth factor-beta-like growth factor by RSV-transformed rat cerebral microvascular endothelial cells. Tumour Biol 1991;12:171-83. https://doi.org/10.1159/000217702
  5. Lamszus K, Jin L, Fuchs A, Shi E, Chowdhury S, Yao Y, et al. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lab Invest 1997;76:339-53.
  6. Desbaillets I, Diserens AC, Tribolet N, Hamou MF, Van Meir EG. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 1997;186:1201-12. https://doi.org/10.1084/jem.186.8.1201
  7. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50. https://doi.org/10.1016/S0163-7258(98)00045-X
  8. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995;373:699-702. https://doi.org/10.1038/373699a0
  9. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48. https://doi.org/10.1038/nrm3012
  10. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103. https://doi.org/10.1038/nrc3205
  11. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41-59. https://doi.org/10.1016/S1359-6101(01)00029-6
  12. Shin SJ, Kim KO, Kim MK, Lee KH, Hyun MS, Kim KJ, et al. Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer. Jpn J Clin Oncol 2005;35:342-8. https://doi.org/10.1093/jjco/hyi094
  13. Chen WC, Obrink B. Cell-cell contacts mediated by E-cadherin (uvomorulin) restrict invasive behavior of L-cells. J Cell Biol 1991;114:319-27. https://doi.org/10.1083/jcb.114.2.319
  14. Althaus E, Karotke E, Nitsch K, Winkler H. An experimental re-examination of the upper stability limit of muscovite plus quartz. Neues Jahrb Miner Monatsh 1970;7:325-36.
  15. Hiscox S, Jiang WG. Hepatocyte growth factor/scatter factor disrupts epithelial tumour cell-cell adhesion: involvement of beta-catenin. Anticancer Res 1999;19:509-17.
  16. Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Kim SW, et al. Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-induced in vitro invasion in human stomach cancer cells. Eur Surg Res 2007;39:208-15. https://doi.org/10.1159/000101452
  17. Markus G, Takita H, Camiolo SM, Corasanti JG, Evers JL, Hobika GH. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res 1980;40:841-8.
  18. Sappino AP, Busso N, Belin D, Vassalli JD. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 1987;47:4043-6.
  19. Markus G, Camiolo SM, Kohga S, Madeja JM, Mittelman A. Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors. Cancer Res 1983;43:5517-25.
  20. Alonso DF, Farias EF, Ladeda V, Davel L, Puricelli L, Bal de Kier Joffe E. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res Treat 1996;40:209-23. https://doi.org/10.1007/BF01806809
  21. Kruger A, Soeltl R, Lutz V, Wilhelm OG, Magdolen V, Rojo EE, et al. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Cancer Gene Ther 2000;7:292-9. https://doi.org/10.1038/sj/cgt/7700144
  22. Lee KH, Bae SH, Lee JL, Hyun MS, Kim SH, Song SK, et al. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Oncology 2004;66:210-7. https://doi.org/10.1159/000077997
  23. Lee KH, Kim SW, Kim JR. Reactive oxygen species regulate urokinase plasminogen activator expression and cell invasion via mitogen-activated protein kinase pathways after treatment with hepatocyte growth factor in stomach cancer cells. J Exp Clin Cancer Res 2009;28:73. https://doi.org/10.1186/1756-9966-28-73
  24. Lee KH, Choi EY, Kim MK, Kim KO, Jang BI, Kim SW, et al. Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer. Mol Cell Biochem 2010;343:163-71. https://doi.org/10.1007/s11010-010-0510-x
  25. Lee KH, Choi EY, Koh SA, Kim MK, Kim KO, Lee SH, et al. Down-regulation of survivin suppresses uro-plasminogen activator through transcription factor JunB. Exp Mol Med 2011;43:501-9. https://doi.org/10.3858/emm.2011.43.9.057
  26. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-91. https://doi.org/10.1016/0092-8674(95)90411-5
  27. Lee KH, Choi EY, Kim MK, Hyun MS, Eun JR, Jang BI, et al. Hepatocyte growth factor promotes cell survival by phosphorylation of BAD in gastric cancer cells. Oncol Res 2008;17:23-32. https://doi.org/10.3727/096504008784046072
  28. Lee JH, Welch DR. Identification of highly expressed genes in metastasis-suppressed chromosome 6/human malignant melanoma hybrid cells using subtractive hybridization and differential display. Int J Cancer 1997;71:1035-44. https://doi.org/10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.0.CO;2-B
  29. Lee JH, Welch DR. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 1997;57:2384-7.
  30. Martin TA, Watkins G, Jiang WG. KiSS-1 expression in human breast cancer. Clin Exp Metastasis 2005;22:503-11. https://doi.org/10.1007/s10585-005-4180-0
  31. Lee KH, Kim JR. Kiss-1 suppresses MMP-9 expression by activating p38 MAP kinase in human stomach cancer. Oncol Res 2009;18:107-16. https://doi.org/10.3727/096504009789954591
  32. Ozanne BW, Spence HJ, McGarry LC, Hennigan RF. Transcription factors control invasion: AP-1 the first among equals. Oncogene 2007;26:1-10. https://doi.org/10.1038/sj.onc.1209759
  33. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3:859-68. https://doi.org/10.1038/nrc1209
  34. Vandel L, Pfarr CM, Huguier S, Loiseau L, Sergeant A, Castellazzi M. Increased transforming activity of JunB and JunD by introduction of an heterologous homodimerization domain. Oncogene 1995;10:495-507.
  35. Tschesche H, Zolzer V, Triebel S, Bartsch S. The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur J Biochem 2001;268:1918-28. https://doi.org/10.1046/j.1432-1327.2001.02066.x
  36. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001;276:37258-65. https://doi.org/10.1074/jbc.M106089200
  37. Lee KH, Kim JR. Regulation of HGF-mediated cell proliferation and invasion through NF-${\kappa}B$, JunB, and MMP-9 cascades in stomach cancer cells. Clin Exp Metastasis 2012;29:263-72. https://doi.org/10.1007/s10585-011-9449-x
  38. Bratt T, Ohlson S, Borregaard N. Interactions between neutrophil gelatinase-associated lipocalin and natural lipophilic ligands. Biochim Biophys Acta 1999;1472:262-9. https://doi.org/10.1016/S0304-4165(99)00131-2
  39. Koh SA, Lee KH. HGF mediated upregulation of lipocalin 2 regulates MMP9 through nuclear factor-${\kappa}B$ activation. Oncol Rep 2015;34:2179-87. https://doi.org/10.3892/or.2015.4189

Cited by

  1. Proteomic Signatures of Diffuse and Intestinal Subtypes of Gastric Cancer vol.13, pp.23, 2021, https://doi.org/10.3390/cancers13235930